Skip to content

US · INGN · MEDICAL - DEVICES

Inogen, Inc. (INGN) intrinsic value and stock valuation

$5.30as of 2026-11-21 · Mkt cap 177.61M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Inogen, Inc. DCF and intrinsic value

InvestorsCraft values INGN with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from INGN’s statements →

Inogen, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Devices Beverly, MA 01915 inogen.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$348.7M+2.5% 5y CAGRd
20112025
Net income
-$-22.75M
20112025
Free cash flow
-$-21.6M
20112025
Total equity
$192.2M-11.3% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$348.7M$335.7M$315.7M$377.2M$358M
Operating income-$-30.21M-$-42.52M-$-109.39M-$-85.24M$9.24M
Net income-$-22.75M-$-35.89M-$-102.45M-$-83.77M-$-6.33M
EPSd-$-837.01K-$-1.52M-$-4.42M-$-3.67M-$-281.46K
Operating cash flow-$-11.22M$5.91M-$-3.23M-$-37.53M$23.6M
Capital expenditure-$-10.38M-$-17.09M-$-26.52M-$-21.22M-$-23.93M
Free cash flow-$-21.6M-$-11.18M-$-29.75M-$-58.75M-$-300K
Total assets$298.6M$296.2M$326.2M$405M$489.5M
Total debt$17.5M$19.4M$21.9M$23.3M$26.7M
Net debt-$-86.25M-$-94.39M-$-103.57M-$-163.74M-$-208.85M
Total equity$192.2M$173.9M$204.8M$297.4M$370.2M
Cash and short-term investments$119.6M$113.8M$128.5M$187M$245.5M
Income statement
20252024202320222021
Revenue$348.7M$335.7M$315.7M$377.2M$358M
Cost of revenue$182.8M$181M$189M$223.7M$181.5M
Gross profit$165.9M$154.7M$126.7M$153.5M$176.5M
Research and development expenses$19.4M$21.6M$20.8M$21.9M$16.6M
Selling, general and administrative expenses$165.1M$175.7M$182.4M$164.7M$150.7M
Other expenses$11.6M$0.00$32.9M$52.2M$0.00
Operating expenses$196.1M$197.3M$236.1M$238.8M$167.2M
Cost and expenses$378.9M$378.2M$425.1M$462.5M$348.8M
Interest income$2.15M$5.19M$6.57M$2.84M$130K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$20.7M$21M$18.2M$23.5M$21.6M
Ebitda-$-2.72M-$-15.47M-$-58.34M-$-9.57M$30.3M
Operating income-$-30.21M-$-42.52M-$-109.39M-$-85.24M$9.24M
Total other income/expenses, net$6.83M$6.04M$7.04M$1.98M-$-580K
Income before tax-$-23.38M-$-36.48M-$-102.34M-$-83.27M$8.66M
Income tax expense-$-630K-$-590K$100K$500K$15M
Net income-$-22.75M-$-35.89M-$-102.45M-$-83.77M-$-6.33M
Weighted average shares outstanding$27.2M$23.7M$23.2M$22.9M$22.5M
Weighted average diluted shares outstanding$27.2M$23.7M$23.2M$22.9M$22.5M
Balance sheet
20252024202320222021
Cash and short-term investments$119.6M$113.8M$128.5M$187M$245.5M
Net receivables$38.9M$30.1M$42.9M$64.4M$25.8M
Inventory$26M$24.8M$21.8M$34.1M$31.9M
Total current assets$198.3M$185.5M$207.1M$304.6M$329.2M
Property, plant and equipment, net$52.9M$62.7M$70.7M$64.9M$63.8M
Goodwill and intangible assets$41.5M$40M$44.7M$33M$93.1M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$100.3M$110.7M$119.1M$100.4M$160.3M
Total assets$298.6M$296.2M$326.2M$405M$489.5M
Accounts payable$20.3M$16.6M$13.5M$18.2M$10.3M
Short-term debt$3.16M$2.81M$3.65M$3.52M$3.39M
Deferred revenue$5.5M$6.65M$7.98M$8.88M$8.57M
Total current liabilities$63.5M$76.7M$72.5M$65.4M$61.5M
Long-term debt$14.3M$16.6M$18.3M$19.8M$23.3M
Deferred revenue, non-current$3.6M$5.75M$8.23M$10.4M$11.9M
Total non-current liabilities$42.9M$45.6M$48.9M$42.3M$57.8M
Capital lease obligations$17.5M$19.4M$21.9M$23.3M$26.7M
Total liabilities$106.4M$122.3M$121.4M$107.6M$119.3M
Common stock$30K$20K$20K$20K$20K
Retained earnings-$-175.58M-$-152.84M-$-116.95M-$-14.5M$69.3M
Accumulated other comprehensive income (loss)$4.24M-$-1.5M$1.23M-$-240K$1.47M
Total equity$192.2M$173.9M$204.8M$297.4M$370.2M
Total investments$15.9M$0.00$2.98M$0.00$9.99M
Total debt$17.5M$19.4M$21.9M$23.3M$26.7M
Net debt-$-86.25M-$-94.39M-$-103.57M-$-163.74M-$-208.85M
Cash flow statement
20252024202320222021
Net income-$-22.75M-$-35.89M-$-102.45M-$-83.77M-$-6.33M
Depreciation and amortization$20.7M$21M$18.2M$23.5M$21.6M
Stock-based compensation$8.01M$7.4M$7.43M$12.3M$10.9M
Change in working capital-$-26.91M-$-4.39M$14.3M-$-44.72M-$-20.07M
Accounts receivable-$-14.62M-$-5.07M$11.1M-$-51.62M-$-5.42M
Inventory-$-3.21M-$-3.54M$7.88M-$-5.6M-$-10.78M
Accounts payable$5.6M-$-3.41M-$-9.18M$6.76M-$-6.48M
Net cash provided by operating activities-$-11.22M$5.91M-$-3.23M-$-37.53M$23.6M
Investments in property, plant and equipment-$-10.38M-$-15M-$-27.01M-$-21.22M-$-24.07M
Acquisitions, net$0.00$0.00-$-29.43M$330K$150K
Net cash used for investing activities-$-26.21M-$-13.97M-$-59.31M-$-10.88M-$-14.64M
Common stock issued$28.2M$810K$1.48M$1.74M$15.7M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$24.2M$270K$960K$380K$15M
Net change in cash-$-12.4M-$-8.08M-$-61.52M-$-48.51M$23.6M
Cash at end of period$105M$117.4M$125.5M$187M$235.5M
Operating cash flow-$-11.22M$5.91M-$-3.23M-$-37.53M$23.6M
Capital expenditure-$-10.38M-$-17.09M-$-26.52M-$-21.22M-$-23.93M
Free cash flow-$-21.6M-$-11.18M-$-29.75M-$-58.75M-$-300K
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Inogen, Inc.

        Inogen, Inc. operates as a medical technology enterprise dedicated to designing, fabricating, and distributing oxygen concentration equipment. These cutting-edge devices are engineered to provide continuous oxygen support for patients managing persistent respiratory conditions. The company's diverse product range features the popular portable Inogen One, which efficiently draws oxygen from the surrounding atmosphere to offer an independent supply, alongside stationary Inogen At Home concentrators, Tidal Assist Ventilators, and various associated accessories. Inogen serves a broad clientele, including individual patients, medical professionals, and insurance providers, both domestically in the United States and globally. Furthermore, the company facilitates direct equipment rentals to patients. Founded in 2001, Inogen, Inc. is headquartered in Goleta, California.

        CEO
        Kevin R. Smith
        Employees
        753
        Beta
        1.59

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of Inogen, Inc. (INGN)?

        InvestorsCraft does not currently publish an intrinsic value for INGN. How the IC value is calculated.

        Is INGN undervalued?

        InvestorsCraft does not publish an undervaluation signal for INGN at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.